Clinical Trial Update: Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) [Phase 3]

View source ↗

Summary

Phase 3 RAMSES real-world study in peanut-allergic children completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• AR101 (peanut oral immunotherapy)

Snippet

Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2021-11-02